Get started
Author

María Teresa Diz-Lois Palomares

Observed names: Diz-Lois M Palomares, M T Diz Lois Palomares, M T Diz-Lois, M T Diz-Lois Palomares, M. Diz-Lois Palomares, M. Teresa Diz-Lois Palomares, M.T. Diz-Lois Palomares, M.� Teresa Diz-Lois Palomares, Maria Teresa Diz-Lois Palomares, María Diz-Lois Palomares, María Teresa Diz-Lois, María Teresa Diz‐Lois Palomares, Mª Teresa Diz-Lois Palomares, Mª. Teresa Diz‐Lois Palomares
ORCID: 0000-0003-3600-8533
Observed ORCID: 0000-0003-3600-8533
OpenAlex ID: A5046794041
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study
2018 · M Chaparro, A Verreth, et al. · The American Journal of Gastroenterology · 171
PDF
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study
2021 · María Chaparro, Ana Garre, et al. · Journal of Clinical Medicine · 106
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
2022 · María Chaparro, Iria Baston-Rey, et al. · Inflammatory Bowel Diseases · 70
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
2022 · María Chaparro, Diana Acosta, et al. · The American Journal of Gastroenterology · 36
Factores predictores de reingreso hospitalario no planificado en pacientes dados de alta de una Unidad de Corta Estancia Médica
2002 · M.T. Diz-Lois Palomares, F. de la Iglesia Martínez, et al. · Anales de Medicina Interna · 18
PDF
P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding
2023 · M Chaparro, M García Donday, et al. · Journal of Crohn s and Colitis · 11
PDF
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence
2024 · Antonio Giordano, Isabel Pérez-Martínez, et al. · The American Journal of Gastroenterology · 7
Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study
2026 · Carmen Yagüe Caballero, Santiago García López, et al. · Alimentary Pharmacology & Therapeutics · 4
PDF
P0692 Comparing JAK inhibitors in ulcerative colitis: which one truly leads in the real world? Results from the ENEIDA registry of GETECCU
2025 · M Chaparro, S Hermida, et al. · Journal of Crohn s and Colitis · 3
PDF
Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study
2021 · Carlos Taxonera, María Pilar Martínez-Montiel, et al. · Therapeutic Advances in Gastroenterology · 3
Factors that predict unplanned hospital readmission of patients discharged from a Short Stay Medical Unit
2002 · M T Diz-Lois Palomares, Fernando de la Iglesia Martínez, et al. · Anales de Medicina Interna · 3
Effectiveness and safety of dual advanced therapy in inflammatory bowel disease ? A multicenter series from Galicia, Spain
2025 · M.� Teresa Diz-Lois Palomares, Carmen Pradera Cibreiro, et al. · Revista Española de Enfermedades Digestivas · 2
Crohn�s disease in patients treated with etanercept
2019 · Eduardo Valdivielso Cortázar, Maria Teresa Diz-Lois Palomares, et al. · Revista Española de Enfermedades Digestivas · 2
P1170 Long-term outcomes of newly diagnosed Inflammatory Bowel Disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU
2024 · M Chaparro, A Garre, et al. · Journal of Crohn s and Colitis · 1
PDF
P675 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases
2023 · M Chaparro, D Acosta, et al. · Journal of Crohn s and Colitis · 1
P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety
2022 · M Chaparro, D Acosta, et al. · Journal of Crohn s and Colitis · 1
Pharmacokinetic and clinical monitoring through posologic change in adalimumab intensification regimen from 40mg every week to 80mg every other week
2022 · M.� Teresa Diz-Lois Palomares, Ángeles Porta Sánchez, et al. · Revista Española de Enfermedades Digestivas · 1
OP20 Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
2021 · M Chaparro, A Garre, et al. · Journal of Crohn s and Colitis · 1
PDF
P263 Influence of Crohn′s Disease phenotype in the retention rate of ustekinumab treatment: SUSTAIN Study
2021 · M Chaparro, I Bastón Rey, et al. · Journal of Crohn s and Colitis · 1
PDF
Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five‐Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease
2026 · Ana Garre, Andrea Nuñez Ortiz, et al. · Alimentary Pharmacology & Therapeutics
P0664 Effectiveness and safety of upadacitinib in ulcerative colitis in clinical practice: results from the U-REAL-UC study from ENEIDA
2025 · M Chaparro, S Hermida, et al. · Journal of Crohn s and Colitis
PDF
P1227 Predictors of biologics/JAKi use, surgeries, and hospitalisations in a newly diagnosed cohort of IBD patients: Long-term outcomes from the nationwide EpidemIBD study of GETECCU
2025 · A Garre, A Núñez Ortiz, et al. · Journal of Crohn s and Colitis
P0744 Observational Real-World Study of Switching from Intravenous to Subcutaneous Vedolizumab in IBD Patients: Clinical and Pharmacokinetic Analysis
2025 · M T Diz Lois Palomares, M Barreiro de-Acosta, et al. · Journal of Crohn s and Colitis
PDF
Efectividad Y Seguridad De Upadacitinib En Colitis Ulcerosa En La Práctica Clínica: Resultados Del Estudio U-real-uc Del Registro Eneida
2025 · María Chaparro, Sandra Hermida, et al. · Gastroenterología y Hepatología
Inhibidores Jak En La Colitis Ulcerosa: ¿cuál Es La Mejor Opción En La Práctica Clínica? Resultados Del Registro Eneida De Geteccu
2025 · María Chaparro, Sandra Hermida, et al. · Gastroenterología y Hepatología
Works count: 38
Citation count: 442
H-index: 7
I10-index: 6
Year
Topic
Type